14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
SBRA vs XRN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBRA carries a Unified Composite Score of 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin), whereas XRN carries 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin).
Technical & Structure Timing Caution: SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8); meanwhile XRN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SBRA vs XRN. Trailing 12-month operating profitability (SBRA 18.4% vs XRN N/A) and valuation multiples (SBRA 30.4x vs XRN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SBRA vs XRN Key Questions & Quantitative Answers
As of Nov 17, 2026, Sabra Healthcare REIT, Inc. (SBRA) is the stronger overall head-to-head candidate over XRN (XRN) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SBRA carries a Unified Composite Score of 57.4/100 (HOLD) at $20.27 (30.4x Forward P/E, 18.4% operating margin), whereas XRN carries 45.3/100 (HOLD) at $25.79 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: SBRA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 50.8); meanwhile XRN is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SBRA leads the Growth & Scale pillar: SBRA posts +31.6% YoY revenue growth and +22.2% YoY earnings growth on $924M TTM revenue (49.6% gross margin, 18.4% operating margin), compared with XRN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, SBRA generates $924M in USD-normalized revenue versus N/A for XRN. In operating R&D and SG&A reinvestment, SBRA deploys 31.2% of Rev ($288M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XRN.
SBRA screens cheaper on headline valuation multiples. SBRA trades at 30.4x Forward P/E, 75.7x Trailing P/E, 5.28x PEG, and 8.4x EV/Revenue (43.3% FCF margin), whereas XRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SBRA (2.5% ROE) versus XRN (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, SBRA carries 27.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.19x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.00β · 30% Vol realized risk). By comparison, XRN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.50β · 47% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.